MedTrace Logo

ImmunoCARE: Rapid, Accurate COVID Testing to Reduce Hospitalization of Immunocompromised Individuals

NCT05655546 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 2117

Last updated 2025-08-08

Study results available
· View outcomes & findings →

Summary

The investigators will examine whether a combination of at-home nucleic acid amplification tests, on-demand telemedicine, and delivery of prescriptions such as Paxlovid quickly after testing positive for COVID-19, can reduce severe outcomes and hospitalization of immunocompromised patients and those who are 65 years and older. They will also analyze whether these efforts lower the cost of care compared to standard of care.

Conditions

Interventions

OTHER

Access to Cue Health COVID-19 Remote testing and treatment for COVID-19

Participants will receive at home COVID-19 test for themselves and others in their household.

Sponsors & Collaborators

  • Cue Health

    collaborator UNKNOWN

  • Scripps Translational Science Institute

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
120 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-12-22
Primary Completion
2024-06-20
Completion
2024-06-20

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05655546 on ClinicalTrials.gov